Surrogate Endpoints in p16-Positive Squamous Cell Carcinoma of the Oropharynx

The increased incidence of HPV-related cancers has motivated efforts to optimize treatment paradigms for these excellent-prognosis patients. Validation of surrogates for overall survival (OS) could expedite the evaluation of new therapies. We sought to validate candidate intermediate clinical endpoints (ICE) in trials assessing definitive treatment of p16-positive oropharyngeal cancer with (chemo)radiation.

Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: L.A. Gharzai, E. Morris, P.F. Nguyen-Tan, D.I. Rosenthal, M. Gillison, P.M. Harari, A.S. Garden, K. Zanotti, J.J. Caudell, C.U. Jones, D.L. Mitchell, G.A. Krempl, J.A. Ridge, M.F. Gensheimer, J.A. Bonner, Q.T. Le, P. Torres-Saavedra, M.L. Mierzwa, M. Schi Tags: 100 Source Type: research